Haleon plc
NYSE:HLNDrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $39.85B
- Beta
- 0.25
- P/E (TTM)
- 29.2
- EPS (TTM)
- $0.11
- Dividend yield
- 2.13%
Volume 19.46M
Average 8.79M
HLN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Haleon plcNYSE: HLN
Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025
Cost of revenue declines year over year
Q4 FY2025 cost of revenue of £1.93B fell 9.8% year over year. Over 3 fiscal years it compounded at -3.6% a year.
Context
- Cost of revenue amounted to 34.7% of revenue in FY2025, down 3.4 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
GBP · from the income statement
- Latest · FY2025
- 3.83B GBP
- Year-over-year change
- -10.6%
- 4-year CAGR
- +1.6%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.83B | -10.6% |
| FY2024 | 2024-12-31 | 4.29B | -1.3% |
| FY2023 | 2023-12-31 | 4.34B | +1.4% |
| FY2022 | 2022-12-31 | 4.28B | +19.1% |
| FY2021 | 2021-12-31 | 3.6B | — |
Cost of Revenue vs competitors
How HLN compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Cost of revenue amounts to 36.8% of revenue for HLN, versus a peer median of 41.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | £9.06B GBP | -0.0% | -1.9% | 27.3% | |
| LTM Sep 2026 | $8.38B USD | +4.7% | +1.3% | 39.4% | |
| LTM Sep 2026 | $6.48B USD | +3.1% | -1.7% | 41.7% | |
| LTM Jun 2025 | £6.09B GBP | — | -3.6% | 36.8% | |
| LTM Sep 2026 | $3.37B USD | -1.3% | +3.1% | 53.9% | |
| LTM Jun 2026 | $2.77B USD | -0.5% | -2.7% | 66.7% | |
| Peer median (excluding HLN) | — | -0.0% | -1.7% | 41.7% | |
Competitors are the stored peer set for HLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.55B | 10.86B | 11.3B | 11.23B | 11.03B |
| Cost of Revenue | 3.6B | 4.28B | 4.34B | 4.29B | 3.83B |
| Gross Profit | 5.95B | 6.58B | 6.96B | 6.95B | 6.99B |
| Gross Margin | 62.3% | 60.6% | 61.6% | 61.9% | 63.3% |
| Research & Development | 257M | 300M | 311M | 298M | 308.1M |
| Selling, General & Admin | 3.79B | 4.04B | 4.29B | 4.33B | 4.36B |
| Operating Expenses | 4.31B | 4.75B | 4.97B | 4.74B | 4.43B |
| Depreciation & Amortization | 268M | 287M | 309M | 196M | 352.11M |
| EBITDA | 2.21B | 2.18B | 2.35B | 2.51B | 2.88B |
| EBITDA Margin | 23.2% | 20.1% | 20.8% | 22.4% | 26.1% |
| Operating Income | 1.64B | 1.83B | 2B | 2.21B | 2.41B |
| Operating Margin | 17.2% | 16.8% | 17.7% | 19.6% | 21.9% |
| Interest Income | 13M | 68.98M | 14M | 55M | 76.29M |
| Interest Expense | 16M | 347.36M | 414M | 394M | 332.55M |
| Other Income / Expenses | (2M) | (207M) | (368M) | (296M) | (260M) |
| Income Before Tax | 1.64B | 1.62B | 1.63B | 1.91B | 2.15B |
| Pre-Tax Margin | 17.1% | 14.9% | 14.4% | 17.0% | 19.5% |
| Income Tax Expense | 197M | 499M | 517M | 435M | 461.66M |
| Net Income | 1.39B | 1.06B | 1.05B | 1.44B | 1.63B |
| Net Margin | 14.6% | 9.8% | 9.3% | 12.8% | 14.8% |
| EPS (Basic) | 0.30 | 0.24 | 0.24 | 0.32 | 0.36 |
| EPS (Diluted) | 0.30 | 0.24 | 0.24 | 0.32 | 0.36 |
| Weighted Avg Shares | 4.62B | 4.62B | 4.63B | 4.57B | 4.48B |
| Weighted Avg Shares (Diluted) | 4.62B | 4.62B | 4.63B | 4.59B | 4.51B |
Haleon plc
NYSE:HLN
Intrinsic Alpha fair value
Locked
Current Price
$9.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.